HRP20200814T1 - Stabilna i topljiva protutijela koja inhibiraju vegf - Google Patents
Stabilna i topljiva protutijela koja inhibiraju vegf Download PDFInfo
- Publication number
- HRP20200814T1 HRP20200814T1 HRP20200814TT HRP20200814T HRP20200814T1 HR P20200814 T1 HRP20200814 T1 HR P20200814T1 HR P20200814T T HRP20200814T T HR P20200814TT HR P20200814 T HRP20200814 T HR P20200814T HR P20200814 T1 HRP20200814 T1 HR P20200814T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- binding fragment
- use according
- fragment
- Prior art date
Links
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000003163 Cavernous Hemangioma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000006395 Meigs Syndrome Diseases 0.000 claims 2
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 108091081024 Start codon Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 208000006359 hepatoblastoma Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000007538 neurilemmoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
Claims (17)
1. Protutijelo ili njegov ulomak koji veže antigen, naznačeno time, da je za uporabu u terapiji ili in vivo dijagnosticiranju, pri čemu protutijelo ili njegov ulomak koji veže antigen obuhvaća varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 164 i varijabilni laki lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 87.
2. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 1, naznačeno time, da se protutijelo ili njegov ulomak koji veže antigen specifično veže na ljudski, štakorski i mišji VEGF.
3. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 1 ili 2, naznačeno time, da je ulomak koji veže antigen scFv, Fab ulomak, Fab' ulomak, ili F(ab')2 ulomak.
4. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je protutijelo ili njegov ulomak koji veže antigen formulirano za topikalnu, intraokularnu, oralnu, nazalnu, rektalnu ili parenteralnu primjenu.
5. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da protutijelo ili njegov ulomak koji veže antigen ima N-terminalni metioninski ostatak u konačnom proteinu dobivenom iz početnog kodona.
6. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da ulomak koji veže antigen je scFv, te su varijabilna regija teškog lanca i varijabilna regija lakog lanca međusobno povezane sekvencom SEQ ID NO: 181.
7. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je za uporabu u liječenju bolesti posredovane s VEGF.
8. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 7, naznačeno time, da je bolest posredovana s VEGF odabrana iz skupine koja se sastoji od makularne degeneracije povezane sa starenjem, neovaskularnog glaukoma, dijabetičke retinopatije, retinopatije nedonoščadi.
9. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 7, naznačeno time, da je bolest posredovana s VEGF odabrana iz skupine koju čine retrolentalna fibroplazija, karcinomi dojke, karcinomi pluća, karcinomi želuca, karcinomi jednjaka, karcinomi debelog crijeva, karcinomi jetre, karcinomi jajnika, sarkomi, arhenoblastomi, karcinomi grlića maternice, karcinom endometrija, hiperplazija endometrija, endometrioza, fibrosarkomi, koriokarcinom, rak glave i vrata, karcinom nazofarinksa, karcinomi larinksa, hepatoblastom, Kaposijev sarkom, melanom, karcinomi kože, hemangiom, kavernozni hemangiom, hemangioblastom, karcinomi gušterače, retinoblastom, astrocitom, glioblastom, schwanom, oligodendrogliom, meduloblastom, neuroblastomi, rabdomiosarkom, osteogeni sarkom, leiomiosarkomi, karcinomi mokraćnog sustava, karcinomi štitnjače, Wilmsov tumor, karcinom bubrežnih stanica, karcinom prostate, abnormalna vaskularna proliferacija povezana s fakomatozama, edem (kao što je onaj povezan s tumorima mozga), Meigsov sindrom, reumatoidni artritis, psorijaza i ateroskleroza.
10. Uporaba protutijela ili njegovog ulomka koji veže antigen, naznačena time, da služi u proizvodnji lijeka za liječenje bolesti posredovane s VEGF, pri čemu protutijelo ili njegov ulomak koji veže antigen obuhvaća varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 164 i varijabilni laki lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 87.
11. Uporaba prema patentnom zahtjevu 10, naznačena time, da se protutijelo ili njegov ulomak koji veže antigen specifično veže na ljudski, štakorski i mišji VEGF.
12. Uporaba prema patentnom zahtjevu 10 ili 11, naznačena time, da ulomak koji veže antigen je scFv, Fab ulomak, Fab' ulomak, ili F(ab')2 ulomak.
13. Uporaba prema bilo kojem od patentnih zahtjeva 10 do 12, naznačena time, da je protutijelo ili njegov ulomak koji veže antigen formulirano za topikalnu, intraokularnu, oralnu, nazalnu, rektalnu ili parenteralnu primjenu.
14. Uporaba prema bilo kojem od patentnih zahtjeva 10 do 12, naznačena time, da protutijelo ili njegov ulomak koji veže antigen ima N-terminalni metioninski ostatak u u konačnom proteinu dobivenom iz početnog kodona.
15. Uporaba prema bilo kojem od patentnih zahtjeva 10 do 14, naznačena time, da ulomak koji veže antigen je scFv, te su varijabilna regija teškog lanca i varijabilna regija lakog lanca međusobno povezane sekvencom iz SEQ ID NO: 181.
16. Uporaba prema bilo kojem od patentnih zahtjeva 10 do 14, naznačena time, da pojedinac ima bolest posredovanu s VEGF odabranu iz skupine koja se sastoji od makularne degeneracije povezane sa starenjem, neovaskularnog glaukoma, dijabetičke retinopatije, retinopatije nedonoščadi.
17. Uporaba prema bilo kojem od patentnih zahtjeva 10 do 14, naznačena time, da pojedinac ima bolest posredovanu s VEGF odabranu iz skupine koju čine retrolentalna fibroplazija, karcinomi dojke, karcinomi pluća, karcinomi želuca, karcinomi jednjaka, karcinomi debelog crijeva, karcinomi jetre, karcinomi jajnika, sarkomi, arhenoblastomi, karcinomi grlića maternice, karcinom endometrija, hiperplazija endometrija, endometrioza, fibrosarkomi, koriokarcinom, rak glave i vrata, karcinom nazofarinksa, karcinomi larinksa, hepatoblastom, Kaposijev sarkom, melanom, karcinomi kože, hemangiom, kavernozni hemangiom, hemangioblastom, karcinomi gušterače, retinoblastom, astrocitom, glioblastom, schwanom, oligodendrogliom, meduloblastom, neuroblastomi, rabdomiosarkom, osteogeni sarkom, leiomiosarkomi, karcinomi mokraćnog sustava, karcinomi štitnjače, Wilmsov tumor, karcinom bubrežnih stanica, karcinom prostate, abnormalna vaskularna proliferacija povezana s fakomatozama, edem (kao što je onaj povezan s tumorima mozga), Meigsov sindrom, reumatoidni artritis, psorijaza i ateroskleroza.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13321208P | 2008-06-25 | 2008-06-25 | |
US7569208P | 2008-06-25 | 2008-06-25 | |
US7569708P | 2008-06-25 | 2008-06-25 | |
US15504109P | 2009-02-24 | 2009-02-24 | |
EP17151756.8A EP3216803B1 (en) | 2008-06-25 | 2009-06-25 | Stable and soluble antibodies inhibiting vegf |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200814T1 true HRP20200814T1 (hr) | 2020-08-07 |
Family
ID=41209803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170615TT HRP20170615T1 (hr) | 2008-06-25 | 2017-04-18 | Stabilna i topiva protutijela koja inhibiraju vegf |
HRP20200814TT HRP20200814T1 (hr) | 2008-06-25 | 2020-05-19 | Stabilna i topljiva protutijela koja inhibiraju vegf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170615TT HRP20170615T1 (hr) | 2008-06-25 | 2017-04-18 | Stabilna i topiva protutijela koja inhibiraju vegf |
Country Status (26)
Country | Link |
---|---|
US (5) | US8349322B2 (hr) |
EP (3) | EP2307454B1 (hr) |
JP (7) | JP5956752B2 (hr) |
KR (8) | KR102013220B1 (hr) |
CN (3) | CN102143976B (hr) |
AU (1) | AU2009264565C1 (hr) |
BR (1) | BRPI0914251B1 (hr) |
CA (2) | CA2727839C (hr) |
CL (1) | CL2010001544A1 (hr) |
CY (3) | CY1118829T1 (hr) |
DK (2) | DK2307454T3 (hr) |
ES (2) | ES2622470T3 (hr) |
HK (1) | HK1150844A1 (hr) |
HR (2) | HRP20170615T1 (hr) |
HU (3) | HUE032894T2 (hr) |
LT (3) | LT2307454T (hr) |
MX (2) | MX2011000011A (hr) |
NL (1) | NL301058I2 (hr) |
NO (1) | NO2020021I1 (hr) |
PH (1) | PH12015501593A1 (hr) |
PL (2) | PL3216803T3 (hr) |
PT (2) | PT2307454T (hr) |
RU (6) | RU2531523C3 (hr) |
SI (2) | SI3216803T1 (hr) |
WO (1) | WO2009155724A2 (hr) |
ZA (1) | ZA201008594B (hr) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
HUE039692T2 (hu) | 2008-06-25 | 2019-01-28 | Esbatech Alcon Biomed Res Unit | TNF-et gátló stabil és oldható ellenanyagok |
PL3216803T3 (pl) | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
EP3130603A1 (en) * | 2008-06-30 | 2017-02-15 | ESBATech, an Alcon Biomedical Research Unit LLC | Functionalized polypeptides |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
CA2744103C (en) | 2009-02-24 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods for identifying immunobinders of cell-surface antigens |
SG176963A1 (en) | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
MX2011013417A (es) | 2009-06-25 | 2012-03-29 | Amgen Inc | Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero. |
CN103429260B (zh) * | 2010-10-19 | 2016-08-10 | 梅奥医学教育和研究基金会 | 用于治疗神经疾病的人抗体及其诊断和治疗用途 |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
EP2758432B1 (en) * | 2011-09-16 | 2019-03-06 | UCB Biopharma SPRL | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
WO2013113820A1 (en) | 2012-02-02 | 2013-08-08 | Esbatech - A Novartis Company Llc | Antibody-containing sustained-release formulation for ocular administration |
HUE056217T2 (hu) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében |
EP2935589A1 (en) | 2012-12-18 | 2015-10-28 | Novartis AG | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
ES2771478T3 (es) | 2013-02-18 | 2020-07-06 | Vegenics Pty Ltd | Moléculas de unión a ligando y usos de las mismas |
KR101541478B1 (ko) | 2013-05-31 | 2015-08-05 | 동아쏘시오홀딩스 주식회사 | 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물 |
AU2014301629B2 (en) | 2013-06-26 | 2020-02-06 | Numab Therapeutics AG | Novel antibody frameworks |
AU2014286996A1 (en) | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
EP3492495A1 (en) | 2014-05-12 | 2019-06-05 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
KR102390359B1 (ko) | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
CN107206080B (zh) * | 2015-01-28 | 2022-07-08 | 辉瑞公司 | 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂 |
EP3283517A4 (en) | 2015-04-16 | 2019-03-06 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
US10851399B2 (en) * | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
US20180230540A1 (en) | 2015-08-12 | 2018-08-16 | Novartis Ag | Methods of treating ophthalmic disorders |
EP3368578B1 (en) | 2015-10-30 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Anti-htra1 antibodies and methods of use thereof |
WO2017082213A1 (ja) * | 2015-11-09 | 2017-05-18 | 国立大学法人京都工芸繊維大学 | ヒト血清由来IgGポリクローナル抗体の分離剤、及び、それを用いたヒト血清由来IgGポリクローナル抗体を分離する方法 |
BR112018009953B1 (pt) | 2015-11-18 | 2024-03-05 | Formycon Ag | Seringa farmacêutica pré-preenchida esterilizada, e, kit |
AU2016356717B2 (en) | 2015-11-18 | 2022-09-29 | Sio2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
JP2019501687A (ja) | 2015-11-18 | 2019-01-24 | フォーマイコン アーゲーFormycon Ag | Vegf拮抗薬を収容したプレフィルドプラスチックシリンジ |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
WO2017119434A1 (ja) | 2016-01-06 | 2017-07-13 | 株式会社オーダーメードメディカルリサーチ | Vegfとnrp1との結合を阻害する抗体 |
US11007259B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | High-affinity anti-VEGF antibody |
USD789171S1 (en) | 2016-01-21 | 2017-06-13 | Nomis Llc | Right angle drive |
JP6953433B2 (ja) | 2016-01-26 | 2021-10-27 | フォーマイコン アーゲーFormycon Ag | Vegfアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ |
MX2018009499A (es) | 2016-02-05 | 2019-05-06 | Univ Texas | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. |
WO2017156423A2 (en) * | 2016-03-11 | 2017-09-14 | Integrated Biotherapeutics, Inc. | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever |
EP3222673A1 (de) * | 2016-03-23 | 2017-09-27 | LANXESS Deutschland GmbH | Metallazopigmente |
CN109311977B (zh) | 2016-04-15 | 2022-06-14 | H.伦德贝克公司 | 人源化的抗pacap抗体及其用途 |
EP3479819B1 (en) | 2016-06-30 | 2024-01-24 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
EP3481963A1 (en) | 2016-07-08 | 2019-05-15 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene. |
WO2018162724A1 (en) * | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
BR112019023795A2 (pt) | 2017-05-19 | 2020-07-28 | Council Of Scientific & Industrial Research | método para produzir ranibizumabe humanizado recombinante redobrado |
WO2018217995A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
EP3630062A2 (en) | 2017-05-24 | 2020-04-08 | SiO2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
CN117946278A (zh) * | 2017-06-25 | 2024-04-30 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
CA3083472A1 (en) | 2017-11-27 | 2019-05-31 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
CN111511400A (zh) | 2017-12-29 | 2020-08-07 | 豪夫迈·罗氏有限公司 | 抗vegf抗体及其使用方法 |
US11078283B2 (en) | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
US20210017266A1 (en) | 2018-03-16 | 2021-01-21 | Novartis Ag | Methods for treating ocular diseases |
WO2019195090A1 (en) * | 2018-04-06 | 2019-10-10 | Eli Lilly And Company | Ramucirumab for the treatment of cancers in pediatric patients |
CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
WO2020047473A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
AU2019328313A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
AU2019339469A1 (en) * | 2018-09-13 | 2021-03-11 | Immune-Onc Therapeutics, Inc. | Novel LILRB4 antibodies and uses thereof |
CN113164597A (zh) | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体 |
JOP20210152A1 (ar) | 2018-12-18 | 2023-01-30 | Novartis Ag | صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf |
USD907456S1 (en) | 2019-05-21 | 2021-01-12 | Nomis Llc | Right angle drill attachment |
USD907455S1 (en) | 2019-05-21 | 2021-01-12 | Nomis Llc | Right angle drive attachment |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
CA3149706A1 (en) | 2019-09-13 | 2021-03-18 | Novartis Ag | Methods for treating ocular diseases |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4103601A2 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
JP2023519106A (ja) | 2020-02-11 | 2023-05-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | クロマトグラフィー樹脂およびその使用 |
US20230340112A1 (en) * | 2020-02-28 | 2023-10-26 | Apexigen, Inc. | Anti-sirpa antibodies and methods of use |
CN115551894A (zh) * | 2020-03-12 | 2022-12-30 | 以明生物免疫医疗公司 | 新型抗lilrb4抗体和衍生产物 |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods for treating disorders related to aging |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
IL299586A (en) | 2020-07-16 | 2023-03-01 | Novartis Ag | Anti-betacellulin antibodies, their fragments, and multispecific binding molecules |
TW202228790A (zh) | 2020-10-15 | 2022-08-01 | 美商建南德克公司 | 用於長效經眼遞送之非共價蛋白質-玻尿酸結合物 |
TW202237181A (zh) | 2020-11-25 | 2022-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
WO2022201084A1 (en) | 2021-03-26 | 2022-09-29 | Novartis Ag | Methods for treating ocular diseases |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
KR20230094450A (ko) | 2021-12-21 | 2023-06-28 | 한림대학교 산학협력단 | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
TW202337496A (zh) | 2022-03-17 | 2023-10-01 | 瑞士商諾華公司 | 治療新生血管性年齡相關性黃斑點退化之方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
OA10149A (en) | 1991-03-29 | 1996-12-18 | Genentech Inc | Vascular endothelial cell growth factor antagonists |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
RO119721B1 (ro) | 1992-10-28 | 2005-02-28 | Genentech Inc. | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
DE69726003T2 (de) * | 1996-07-16 | 2004-08-26 | Andreas Plückthun | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
WO2000053760A2 (en) * | 1999-03-12 | 2000-09-14 | Genentech, Inc. | Method of preventing the death of retinal neurons and treating ocular diseases |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP1325932B9 (en) * | 1997-04-07 | 2006-07-19 | Genentech, Inc. | Anti-vegf antibodies |
ATE476664T1 (de) * | 1997-04-07 | 2010-08-15 | Genentech Inc | Anti-vegf antikörper |
WO2000034337A1 (en) * | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
KR100816572B1 (ko) | 1999-04-28 | 2008-03-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-vegf 항체 및 이를 포함하는 약제학적 조성물 |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
JP2003527334A (ja) * | 1999-10-22 | 2003-09-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | A33抗原特異的免疫グロブリン産物を用いるa33抗原を発現する癌の影響を低減する方法 |
ATE273323T1 (de) | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
DE10201450B4 (de) | 2002-01-16 | 2004-09-02 | Infineon Technologies Ag | Carry-Skip-Addierer für verschlüsselte Daten |
US6576941B1 (en) | 2002-02-20 | 2003-06-10 | Samsung Electronics Co., Ltd. | Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof |
CN1187373C (zh) * | 2002-03-20 | 2005-02-02 | 上海中信国健药业有限公司 | 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物 |
WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
AU2003238370B2 (en) | 2002-05-22 | 2010-04-29 | Novartis Ag | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
WO2004016740A2 (en) * | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
KR20180132969A (ko) | 2003-05-30 | 2018-12-12 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US20050048578A1 (en) * | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
CN100415765C (zh) * | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
CA2575901C (en) | 2004-08-02 | 2015-01-27 | Amrad Operations Pty. Ltd. | A method of treating cancer comprising a vegf-b antagonist |
EP2311433A3 (en) | 2004-10-21 | 2011-08-10 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
JP2009504685A (ja) * | 2005-08-15 | 2009-02-05 | アラーナ・テラピューティクス・リミテッド | 新世界霊長類フレームワーク領域を用いる設計された抗体 |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
WO2007140534A1 (en) * | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
SI2046382T1 (sl) | 2006-07-10 | 2016-12-30 | ESBATech an Alcon Biomedical Research Unit LLC | Protitelesa scFv, ki prehajajo epitelijske in/ali endotelijske plasti |
AU2007323925A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
US7553486B2 (en) | 2006-11-13 | 2009-06-30 | Paul Theodore Finger | Anti-VEGF treatment for radiation-induced vasculopathy |
TW200831538A (en) | 2006-12-19 | 2008-08-01 | Genentech Inc | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
EP2164961B1 (en) | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
EP2259795B1 (en) * | 2008-03-26 | 2016-04-06 | Epitomics, Inc. | Anti-vegf antibody |
DK3241843T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Opløselighedsoptimering af immunbindere |
KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
PL3216803T3 (pl) | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
KR20110031373A (ko) * | 2008-07-10 | 2011-03-25 | 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 | 마크로분자 전달을 증강하는 방법 및 조성물 |
CA2777527C (en) * | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
-
2009
- 2009-06-25 PL PL17151756T patent/PL3216803T3/pl unknown
- 2009-06-25 ES ES09768693.5T patent/ES2622470T3/es active Active
- 2009-06-25 RU RU2011102583A patent/RU2531523C3/ru active
- 2009-06-25 RU RU2014132888A patent/RU2588467C3/ru active Protection Beyond IP Right Term
- 2009-06-25 AU AU2009264565A patent/AU2009264565C1/en active Active
- 2009-06-25 BR BRPI0914251-7A patent/BRPI0914251B1/pt active IP Right Grant
- 2009-06-25 CA CA2727839A patent/CA2727839C/en active Active
- 2009-06-25 LT LTEP09768693.5T patent/LT2307454T/lt unknown
- 2009-06-25 LT LTEP17151756.8T patent/LT3216803T/lt unknown
- 2009-06-25 EP EP09768693.5A patent/EP2307454B1/en active Active
- 2009-06-25 KR KR1020117001961A patent/KR102013220B1/ko active Protection Beyond IP Right Term
- 2009-06-25 US US13/000,423 patent/US8349322B2/en active Active
- 2009-06-25 KR KR1020167030125A patent/KR101737466B1/ko active IP Right Grant
- 2009-06-25 EP EP17151756.8A patent/EP3216803B1/en active Active
- 2009-06-25 KR KR1020197022648A patent/KR102157097B1/ko active Application Filing
- 2009-06-25 WO PCT/CH2009/000220 patent/WO2009155724A2/en active Application Filing
- 2009-06-25 KR KR1020187024733A patent/KR102095257B1/ko active Protection Beyond IP Right Term
- 2009-06-25 KR KR1020177012884A patent/KR101817284B1/ko active IP Right Grant
- 2009-06-25 PT PT97686935T patent/PT2307454T/pt unknown
- 2009-06-25 CN CN200980124313.5A patent/CN102143976B/zh active Active
- 2009-06-25 SI SI200932061T patent/SI3216803T1/sl unknown
- 2009-06-25 MX MX2011000011A patent/MX2011000011A/es active IP Right Grant
- 2009-06-25 HU HUE09768693A patent/HUE032894T2/hu unknown
- 2009-06-25 DK DK09768693.5T patent/DK2307454T3/en active
- 2009-06-25 CN CN201910338494.7A patent/CN110372792A/zh active Pending
- 2009-06-25 KR KR1020157032314A patent/KR101671886B1/ko active Protection Beyond IP Right Term
- 2009-06-25 ES ES17151756T patent/ES2793008T3/es active Active
- 2009-06-25 DK DK17151756.8T patent/DK3216803T3/da active
- 2009-06-25 PT PT171517568T patent/PT3216803T/pt unknown
- 2009-06-25 SI SI200931647A patent/SI2307454T1/sl unknown
- 2009-06-25 MX MX2013004871A patent/MX347972B/es unknown
- 2009-06-25 CA CA3020290A patent/CA3020290A1/en active Pending
- 2009-06-25 JP JP2011515049A patent/JP5956752B2/ja active Active
- 2009-06-25 HU HUE17151756A patent/HUE050230T2/hu unknown
- 2009-06-25 PL PL09768693T patent/PL2307454T3/pl unknown
- 2009-06-25 KR KR1020187000324A patent/KR20180005753A/ko active IP Right Grant
- 2009-06-25 EP EP20158159.2A patent/EP3722310A1/en active Pending
- 2009-06-25 CN CN201510205513.0A patent/CN104961828B/zh active Active
- 2009-06-25 KR KR1020207026266A patent/KR102296443B1/ko active IP Right Grant
-
2010
- 2010-11-30 ZA ZA2010/08594A patent/ZA201008594B/en unknown
- 2010-12-23 CL CL2010001544A patent/CL2010001544A1/es unknown
-
2011
- 2011-05-19 HK HK11104959.8A patent/HK1150844A1/zh unknown
-
2012
- 2012-12-07 US US13/708,575 patent/US9090684B2/en active Active
-
2013
- 2013-07-19 RU RU2013133802/10A patent/RU2013133802A/ru not_active Application Discontinuation
-
2014
- 2014-04-21 JP JP2014087194A patent/JP6100199B2/ja active Active
-
2015
- 2015-02-27 JP JP2015037794A patent/JP2015134792A/ja active Pending
- 2015-06-16 US US14/741,430 patent/US9873737B2/en active Active
- 2015-07-20 PH PH12015501593A patent/PH12015501593A1/en unknown
-
2016
- 2016-05-18 RU RU2016119152A patent/RU2648152C2/ru active
- 2016-12-28 JP JP2016255720A patent/JP6527128B2/ja active Active
-
2017
- 2017-04-12 CY CY20171100436T patent/CY1118829T1/el unknown
- 2017-04-18 HR HRP20170615TT patent/HRP20170615T1/hr unknown
- 2017-11-16 US US15/814,784 patent/US10590193B2/en active Active
-
2018
- 2018-02-05 JP JP2018018375A patent/JP6821612B2/ja active Active
- 2018-02-16 RU RU2018105866A patent/RU2696972C1/ru active
-
2019
- 2019-05-13 JP JP2019090735A patent/JP6978468B2/ja active Active
- 2019-06-27 RU RU2019120079A patent/RU2747735C3/ru active
-
2020
- 2020-01-31 US US16/779,028 patent/US20200172608A1/en not_active Abandoned
- 2020-05-19 HR HRP20200814TT patent/HRP20200814T1/hr unknown
- 2020-06-05 CY CY20201100507T patent/CY1123028T1/el unknown
- 2020-07-23 LT LTPA2020004C patent/LTC2307454I2/lt unknown
- 2020-07-27 HU HUS2000028C patent/HUS2000028I1/hu unknown
- 2020-07-28 NL NL301058C patent/NL301058I2/nl unknown
- 2020-07-30 CY CY2020026C patent/CY2020026I2/el unknown
- 2020-08-04 NO NO2020021C patent/NO2020021I1/no unknown
-
2021
- 2021-11-11 JP JP2021184262A patent/JP7171877B6/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200814T1 (hr) | Stabilna i topljiva protutijela koja inhibiraju vegf | |
JP2017055774A5 (hr) | ||
AU2021290305B2 (en) | Nanobody dimers linked via C-terminally engineered cysteins | |
JP2018108081A5 (hr) | ||
HRP20170524T1 (hr) | Humana protutijela koja vežu humani protein 4 nalik angiopoietinu | |
CA2971278C (en) | Cysteine linked nanobody dimers | |
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
HRP20190762T1 (hr) | Protutijela koja se vežu prvenstveno na izvanstaničnu domenu 4 ljudskog csf1r i njihova uporaba | |
AU2015276155B2 (en) | Anti-axl antibodies | |
JP2022101693A5 (hr) | ||
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
JP2018070648A5 (hr) | ||
HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
RU2010141584A (ru) | Антитело против csf-1r | |
RU2018100424A (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
JP2011207882A5 (hr) | ||
JP2012502938A5 (hr) | ||
HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
JP2009539403A5 (hr) | ||
JP2010535713A5 (hr) | ||
Fukunaga et al. | Improvement of antibody affinity by introduction of basic amino acid residues into the framework region | |
JP2010516708A5 (hr) | ||
JP2013511288A5 (hr) |